Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ReNEW: A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)

NCT06373731 is registered in ClinicalTrials.gov with Stealth BioTherapeutics Inc. as lead sponsor.

NCT NCT06373731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06373731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ReNEW: A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)
Lead sponsor
Stealth BioTherapeutics Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 30, 2024
Completion date
September 30, 2027
Enrollment
313 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration (armd)